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Abstract: Prostate cancer (PCa) is the second leading cause of cancer death in the United States.
The five-year survival rate for men diagnosed with localized PCa is nearly 100%, yet for those
diagnosed with aggressive PCa, it is less than 30%. The pleiotropic cytokine Interleukin-24 (IL-24) has
been shown to specifically kill PCa cells compared to normal cells when overexpressed in both in vitro
and in vivo studies. Despite this, the mechanisms regulating IL-24 in PCa are not well understood.
Since specific microRNAs (miRNAs) are dysregulated in PCa, we used miRNA target prediction
algorithm tools to identify miR-4719 and miR-6556-5p as putative regulators of IL-24. This study
elucidates the expression profile and role of miR-4719 and miR-6756-5p as regulators of IL-24 in
PCa. qRT-PCR analysis shows miR-4719 and miR-6756-5p overexpression significantly decreases the
expression of IL-24 in PCa cells compared to the negative control. Compared to the indolent PCa
and normal prostate epithelial cells, miR-4719 and miR-6756-5p are significantly overexpressed in
castration-resistant prostate cancer (CRPC) cell lines, indicating that their gain may be an early event
in PCa progression. Moreover, miR-4719 and miR-6756-5p are significantly overexpressed in the
CRPC cell line of African-American males (E006AA-hT) compared to CRPC cell lines of Caucasian
males (PC-3 and DU-145), indicating that miR-4719 and miR-6756-5p may also play a role in racial
disparity. Lastly, the inhibition of expression of miR-4719 and miR-6756-5p significantly increases
IL-24 expression and inhibits proliferation and migration of CRPC cell lines. Our findings indicate
that miR-4719 and miR-6756-5p may regulate CRPC progression through the targeting of IL-24
expression and may be biomarkers that differentiate between indolent and CRPC. Strategies to inhibit
miR-4719 and miR-6756-5p expression to increase IL-24 in PCa may have therapeutic efficacy in
aggressive PCa.
Keywords: microRNA; castration-resistant prostate cancer; Interleukin-24; racial disparity

1. Introduction
Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of
cancer-related death for men in the US [1–3]. Accounting for 180,890 new cases in the United States in
2016, PCa is a major cause of cancer morbidity and mortality [1–3]. The annual morbidity grows as
the rate of PCa has increased by 14% over the last two decades [4–6]. Despite this, men with PCa do
not die from localized prostate cancer but instead, castration-resistant prostate cancer (CRPC) [4,5,7].
In the US, the average 5-year survival rate for localized PCa is 100%, but for CRPC it is less than
30% [7–9]. Prostate specific antigen (PSA), the current tool for screening for PCa, is highly controversial
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because it is not PCa-specific and has a high false positive rate [7–10]. Consequently, new biomarkers
are urgently needed for the early detection of PCa, and it is crucial that these novel biomarkers are
sensitive enough to discriminate between indolent PCa and CRPC.
Interleukin-24 (IL-24), also known as melanoma differentiation associated gene-7, is a
multifunction cytokine that has been studied for its specific anti-cancer properties. Along with killing
other cancer cell types, IL-24 induces apoptosis in prostate cancer cells through endoplasmic reticulum
(ER) stress, mitochondrial dysfunction, reactive oxygen species accumulation, and downregulation
of anti-apoptotic proteins [11–16]. In combination with treatments such as ionizing radiation and
Sabutoclax, IL-24 can also sensitize prostate cancer tumors to apoptosis [17,18]. While several in vitro
and in vivo studies have characterized IL-24 as specific cancer killing protein in PCa cells compared
to normal prostate epithelial cells, IL-24 expression in PCa, specifically in CRPC cells, is not fully
understood [11,12,15,17,19–27]. Here, we seek to understand the factors that may increase IL-24’s
short mRNA half-life leading to the upregulation of IL-24 protein and thus, increased apoptosis in PCa
and CRPC.
MicroRNAs (miRNAs) are 20-24-nucleotide-short RNAs that play pivotal roles in almost all
biological processes in mammalian species [28–30]. It is well established that miRNAs are dysregulated
in many cancers, including PCa [5,6,28–35]. MiRNAs can play either the role of an oncogene
when they target tumor suppressor genes and similarly as tumor suppressors when they target
oncogenes [5,6,28–35]. Dysregulation of miRNAs signatures are not rare but rather the rule of human
cancer, including PCa [5,6,28–35]. Thus, miRNA profiling has been a potent tool in identifying
predictive miRNA signatures associated with the progression of various cancers [5,6,28–35].
Based on miRNA target prediction algorithm tools, TARGETSCAN (http://www.targetscan.
org/vert_72/) and miRDB (http://mirdb.org/), microRNA-4719 and miRNA-6756-5p have been
predicted to target the 3’ untranslated region (3’UTR) of IL-24 mRNA. The present study aims to
examine the expression, function, and molecular mechanisms of action of miR-4719 and miR-6756-5p
targeting of IL-24 in PCa progression in vitro. We discovered that miR-4719 and miR-6756-5p are
significantly overexpressed in CRPC cell lines and particularly in African American men (AAM).
Furthermore, IL-24 mRNA is decreased in all PCa cells compared to normal prostate epithelial cells
and we demonstrate that inhibition of miR-4719 and miR-6756-5p increases IL-24 expression and
significantly inhibits proliferation and migration of CRPC cell lines.
These discoveries of novel miRNA-based targeting of IL-24 may improve understanding of the
molecular mechanisms in the development of CRPC and provide opportunities to explore clinical
applications of miR-4719 and miR-6756-5p in PCa. In addition, understanding the mechanism in which
IL-24 mRNA is stabilized could lead to the development of therapeutic strategies that prolong IL-24
mRNA half-life enabling enhanced killing in tumor cells.
2. Results
2.1. MicroRNA-4719 and MicroRNA-6756-5p Are Significantly Overexpressed in Castration-Resistant
Prostate Cancer (CRPC) Cells
Based on the predicted results from two miRNA molecular target prediction algorithms,
TARGETSCAN and miRDB, we identified miR-4719 and miR-6756-5p as putative regulators of IL-24.
These two microRNAs have never been studied in their regulation of IL-24 nor are there any known
reports on the roles of miR-4719 and miR-6756-5p in PCa. To investigate the expression profiles,
functional roles, and the molecular mechanisms of miR-4719 and miR-6756-5p as regulators of IL-24 in
PCa biology, our work compares five different PCa cell lines, modeling different clinical characteristics
of PCa, including E006AA (indolent PCa), E006AA-hT (CRPC), DU-145 (CRPC), and PC-3 (CRPC),
in a non-tumorigenic prostate epithelial cell line, RWPE1 (Figure 1A).
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Cell Line

Sex

Race
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Cancer
Status
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Figure 1. miR-4719 and miR-6756-5p are overexpressed in PCa cells and miR-4719 and miR-6756-5p
inhibitors and mimics affect miR-4719 and miR-6756-5p expression. (A) Characterization of human
cell lines used. qRT-PCR experiments were performed in quadruplicates. (B,C) MiR-4719 and
miR-6756-5p levels were measured in DU-145, PC-3, E006AA, E006AA-hT and RWPE-1 cell lines.
(D–G) A dose-response test of the effect of a transiently transfected inhibitor and a mimic of miR-4719
and miR-6756-5p on miR-4719 and miR-6756-5p expression was performed on and measured against a
50 nM non-targeting negative control. Data are presented as mean ± standard error of the mean (SEM).
Statistical differences were determined with one-way ANOVA; All the criterions for significance was
set at p < 0.05.

qRT-PCR analysis shows that miR-4719 and miR-6756-5p are both significantly overexpressed in
all PCa cell lines (by >2-fold) compared to the normal prostate epithelial cell line, RWPE-1 (Figure 1B,C).
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We observed that both miR-4719 (by at least 50%) and miR-6756-5p (>2-fold) are higher in CRPC
cell lines compared to the indolent E006AA PCa cell line, indicating their gain may be an early
event in PCa progression (Figure 1A,B). Additionally, both miR-4719 and miR-6756-5p expression
were higher by (>3-fold) in the CRPC cell line E006AA-hT compared to indolent cell line-E006AA
(Figure 1A,B). Interestingly, miR-4719 and miR-6756-5p is more significantly overexpressed in the
CRPC of African-American men (AAM) (E006AA-hT) compared to aggressive PCa cell lines for
Caucasian men (CM) (PC-3 and DU-145) (Figure 1A,B).
To elucidate the functional roles of miR-4719 and miR-6756-5p expression in PCa, commercially
available synthetic oligonucleotide mimics of miR-4719 and miR-6756-5p (miR-4719 mimic and
miR-6756-5p mimic), synthetic oligonucleotide inhibitors of miR-4719 and miR-6756-5p (miR-4719
inhibitor and miR-6756-5p inhibitor), or a synthetic non-targeting negative control oligonucleotide
(negative control) were transfected into the cells using Lipofectamine® RNAiMAX. A dose-response
experiment analyzed using qRT-PCR confirmed that the miR-4719 mimic and miR-6756-5p mimic
increases endogenous expression of miR-4719 and miR-6756-5p, respectively, in a dose dependently
fashion (Figure 1D,E). Similarly, the miR-4719 inhibitor and miR-6756-5p inhibitor decreases
endogenous miR-4719 and miR-6756-5p expression, respectively, in a dose-dependent fashion
(Figure 1F,G). A 50-nM concentration of both the mimics and inhibitors of miR-4719 and miR-6756-5p
showed maximal specific effect on miR-4719 and miR-6756-5p expression. Consequently, the 50 nM
dose was used to determine the roles of miR-4719 and miR-6756-5p in regulating proliferation and
migration in CRPC cells.
2.2. IL-24 Is Downregulated in All Prostate Cancer Cells and microRNA-4719 and microRNA-6756-5p
Targets IL-24
Using our panel of PCa cell lines, we discovered that IL-24 expression is downregulated in
aggressive CRPC cell lines compared to indolent PCa and the normal prostate epithelial cell line,
RWPE-1 (Figure 2A). Our data reveals that IL-24 expression is lower in the CRPC cell lines PC-3,
DU-145 and E006AA-hT cell lines when compared to its indolent counterpart, E006AA (Figure 2A).
This suggests that loss of IL-24 is associated with the progression to CRPC.
We next investigated if IL-24 may possibly be a molecular target of miR-4719 and miR-6756-5p.
Consequently, we assessed the effect of the microRNA mimics (overexpression) and inhibitors (loss)
of miR-4719 and miR-6756-5p on IL-24 mRNA expression in the RWPE-1, E006AA-hT and PC-3 PCa
cell lines (Figure 2B–G). qRT-PCR analysis show inhibition of miR-4719 and miR-6756-5p significantly
increases the expression of IL-24 in RWPE-1 cells (~20%), E006AA-hT cells (~2.5 fold) and PC-3
cells (nearly 2-fold) compared to the negative control. In contrast, overexpression of miR-4719 and
miR-6756-5p reveals significant decrease in IL-24 expression. Therefore, our findings indicate that
miR-4719 and miR-6756-5p both regulate IL-24 expression in PCa cells. Strategies to inhibit miR-4719
and miR-6756-5p expression to increase IL-24 may have therapeutic efficacy in PCa.
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Figure 2.
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of microRNA
Figure
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of 50 nM concentration
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± standard error of the mean. Statistical differences were determined with one-way ANOVA. All the criterions for significance was set at p < 0.05.
mean ± standard error of the mean. Statistical differences were determined with one-way ANOVA. All the criterions for significance was set at p < 0.05.
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Interestingly, overexpression of miR-4719 and miR-6756-5p led to an even higher proliferative
rate in the CRPC AAM PCa cell line E006AA-hT by at least 30% compared to the proliferative rate
of the CRPC CM PCa cell line, PC-3. Similarly, loss of miR-4719 and miR-6756-5p led to a more
reduced proliferative rate in the CRPC AAM PCa cell line E006AA-hT by at least 20% compared to
the proliferative rate of the CRPC CM PCa cell line, PC-3. Overall, the data demonstrate that loss of
miR-4719 and miR-6756-5p significantly inhibited cellular proliferation in CRPC.
2.4. Loss of miR-4719 and miR-6756-5p Significantly Inhibits Migration in CRPC Cells
Lastly, wound healing assays were performed to assess effect of the mimics and inhibitors of
miR-4719 and miR-6756-5p on migration of the CRPC PC-3 and E006AA-hT cell lines (Figure 4). Wound
healing assays reveal that inhibition of miR-4719 and miR-6756-5p reduced migration by approximately
50% compared to the negative control of the CM cell line, PC-3 (Figure 4A,B). We observed that
inhibition of miR-4719 and miR-6756-5p more effectively reduced the migration of CRPC E006AA-hT
cells compared to the negative control, by ~60% and ~80%, respectively (Figure 4C,D). Strikingly,
overexpression of miR-4719 and miR-6756-5p increased the migratory capacity of both CRPC cell lines,
in PC-3 by greater than 2-fold and in E006AA-hT by at least 3-fold (Figure 4A–D). Taken together,
loss of miR-4719 and miR-6756-5p inhibited proliferation and migration in CRPC cell lines.
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Figure 4. miR-4719 and miR-6756-5p loss significantly inhibits migration in CRPC. Transfection of
a mimic or inhibitor of miR-4719 and miR-6756-5p was performed. (A–D) Effect of overexpression
of miR-4719 & miR-6756-5p and inhibition of miR-4719 & miR-6756-5p expression on cell migration
assessed using the wound healing assay. Statistical differences were determined with one-way ANOVA.
Data are presented as mean ± standard error of the mean. All the criterions for significance was set at
p < 0.05.
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3. Discussion
The chief obstacle in detecting and treating prostate cancer (PCa) is understanding the molecular
mechanisms involved in the progression of indolent tumors to lethal castrate-resistant prostate cancer
(CRPC) [1,2,7]. Understanding the molecular mechanisms is essential for the discovery of robust
prognostic markers that can identify patients with the greatest risk of relapse and optimize management
strategies to control PCa progression [1,2,7,9]. Thus, in cancer biology, microRNAs (miRNAs) studies
have become important for the discovery of miRNA-based diagnostic, prognostic and theranostic
biomarkers [5,6,28–35]. Changes in miRNA levels can provide critical information on a disease’s
molecular signature status through the course of treatment and recurrence without the need for a
biopsy [5,6,28–35].
Here, we have presented the rationale for investigating the novel roles of microRNA-4719
and microRNA-6756-5p in respect to Interleukin-24 (IL-24) in PCa. The miRNA mechanisms
regulating IL-24 mRNA or protein levels have not been fully delineated in the progression of PCa.
When overexpressed, IL-24 kills PCa cells through several pathways. IL-24 can cause mitochondrial
dysfunction, reactive oxygen species production, and calcium mobilization leading to apoptosis in
PCa cell lines [12]. IL-24 can also downregulate anti-apoptotic proteins such as Bcl-2 and Bcl-xL
and produce of tumor-suppressing ceramides leading to endoplasmic reticulum stress, autophagy,
and apoptosis in PCa [11–16,36]. In mouse PCa xenografts, IL-24 decreases the levels of secreted
soluble clusterin (sCLU) protein, which is linked to resistance to chemotherapy and radiation and
hormone therapies, leading to reduced tumor growth and angiogenesis [37]. Supporting these studies,
IL-24 has been found to reduce factors of stemness such as migration, invasion, colony formation and
inhibit the expression of SOX2 transcription factor, CD44 cell-surface glycoprotein and ATP Binding
Cassette Subfamily G Member 2 (ABCG2) compared to other cytokines, IL-3, IL-6 and IL-11 in PCa
cells [26]. In combination with ionizing radiation, IL-24 is also able to induce apoptosis in PCa cells
overexpressing Bcl-2 and Bcl-xL proteins that would normally exhibit resistance to IL-24 treatment
alone [17]. Combination treatment of Sabutoclax, an inhibitor of prosurvival myeloid cell leukemia
(Mcl-1) protein, with IL-24 also sensitizes prostate cancer tumors to IL-24-mediated apoptosis [18].
In terms of IL-24 expression regulation in cancer cells, two studies have demonstrated that IL-24
mRNA regulation occurs at the 3’ untranslated region (3’UTR) end via activation of p38MAPK [13,38].
In addition, miRNA-205, which is silenced in human prostate cell lines, has been shown to directly
target the IL-24 promoter to induce gene expression in human PCa and oral cancer cells [25,38].
Furthermore, IL-24 mRNA has been reported to have a relatively short half-life (~20 min) due to the
presence of three AU-rich elements (ARE-sequences), which are targets for RNA-binding proteins
leading to mRNA destabilization and degradation [38].
In this study, we describe for the first time an IL-24/miR-4719 and IL-24/miR-6756-5p regulatory
pathway in PCa which has important clinical implications as miRNAs possess several key features
that make them attractive PCa biomarkers (Figure 5). We discovered that the expression of miR-4719
and miR-6756-5p is significantly overexpressed in PCa cells (Figure 1). Furthermore, both microRNAs
demonstrate differential expression between indolent and CRPC. We also demonstrate expression of
miR-4719 and miR-6756-5p in PCa cells significantly increases cancer cell proliferation and migration
(Figures 3 and 4). As predicted, we show that miRNA-4719 and miRNA-6756-5p inhibitors also
increase the expression of IL-24 mRNA and also significantly inhibit PCa and CRPC proliferation
and migration (Figures 2–4). As miRNAs are known to be involved in the destabilization of mRNA
thus, reducing expression of proteins such as tumor suppressors, and we show that miRNA-4719 and
miRNA-6756-5p decreases IL-24 expression, it is possible that miRNA-4719 and miRNA-6756-5p are
involved in post-transcriptional modification of IL-24 by destabilizing IL-24 3’UTR, thus, shortening
IL-24’s half-life.
To increase IL-24’s specific killing effect, miRNA-4719 and miRNA-6756-5p oligonucleotide
inhibitors could be used in conjunction with IL-24 treatment to increase endogenous production of
IL-24 and thus, increase apoptosis in cancer cells. It has been shown that miRNAs can simultaneously
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modulate several cancer-relevant gene pathways and can be exploited to increase the sensitivity of
tumor cells to conventional anticancer agents [29,31,33,39–41]. Due to the potential to be one-hit
multi-target therapeutic agents against PCa, miRNAs are interesting drug candidates [28,31,39,42].
Furthermore, our functional experiments clearly demonstrate a mechanism by which miR-4719 and
miR-6756-5p regulate key cellular processes that are dysregulated in the development and progression
of PCa thus, strategies to reduce miR-4719 and miR-6756-5p in PCa may have therapeutic value in
CRPC. In terms of diagnostic significance, the increased levels of miR-4719 and miR-6756-5p expression
in CRPC cells compared to normal prostate epithelial cells indicates that both miRNAs may potentially
serve as biomarkers to risk stratify PCa. Further studies using clinical samples are needed to test
the potential of miR-4719 and miR-6756-5p as biomarkers, however. Interestingly, a recent study
showed that circulating miRNA-6756-5p along with miR-1246, and miR-8073 were successfully used
as biomarkers to detect breast cancer with a 97.1% accuracy [43]. Along with our work, this suggests
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Along with studying how miRNA-4719 and miRNA-6756-5p affects IL-24 expression, we also
To increase IL-24’s specific killing effect, miRNA-4719 and miRNA-6756-5p oligonucleotide
investigated the impact of racial disparity in PCa since African American men (AAM) have a
inhibitors could be used in conjunction with IL-24 treatment to increase endogenous production of
2-fold higher chance of getting aggressive PCa and disparities in tumor aggressiveness remain after
IL-24 and thus, increase apoptosis in cancer cells. It has been shown that miRNAs can simultaneously
controlling for social determinants [32,44–48]. To address this high mortality, effective early detection
modulate several cancer-relevant gene pathways and can be exploited to increase the sensitivity of
and therapeutic strategies are needed [32,44–48]. In this regard, we discovered that miR-4719 and
tumor cells to conventional anticancer agents [29,31,33,39–41]. Due to the potential to be one-hit
miR-6756-5p seems to directly correlate with aggressive PCa cell lines and is differentially expressed
multi-target therapeutic agents against PCa, miRNAs are interesting drug candidates[28,31,39,42].
between Caucasian men (CM) and AAM cell lines tested in our study (Figure 1B,C). Moreover,
Furthermore, our functional experiments clearly demonstrate a mechanism by which miR-4719 and
miR-4719 and miR-6756-5p significantly inhibited IL-24 expression more potently in the AAM cell
miR-6756-5p regulate key cellular processes that are dysregulated in the development and
line compared to the CM cell lines (Figure 2D–G). The data suggests that miR-4719 and miR-6756-5p
progression of PCa thus, strategies to reduce miR-4719 and miR-6756-5p in PCa may have therapeutic
may play a role in explaining the disproportionately increased aggressiveness of PCA in AAM.
value in CRPC. In terms of diagnostic significance, the increased levels of miR-4719 and miR-6756-5p
expression in CRPC cells compared to normal prostate epithelial cells indicates that both miRNAs
may potentially serve as biomarkers to risk stratify PCa. Further studies using clinical samples are
needed to test the potential of miR-4719 and miR-6756-5p as biomarkers, however. Interestingly, a
recent study showed that circulating miRNA-6756-5p along with miR-1246, and miR-8073 were
successfully used as biomarkers to detect breast cancer with a 97.1% accuracy [43]. Along with our
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A limitation of our study is the small sample size. The problem lies in the fact that the majority of
established PCa cell lines are derived from Caucasian men (CM) patients. To date, there are only
four authentic and spontaneously transformed African American men (AAM) PCa cell lines [47,48].
These include E006AA (primary PCa cell line), E006AA-ht (a subline of E006AA), MDA-PCa2a and
MDA-PCa2b [47,48]. In our study, we were able to compare these two proven cell lines, (E006AA
and E006AA-ht) derived from AAM with different clinical characteristics which are clinically relevant
and compared them against three cell lines from CM with different clinical characteristics (RWPE-1,
PC-3, and DU-145). In future studies, we intend to investigate miR-4719 and miR-6756-5p in prostate
cancer tissue samples derived from both AAM and CM. The discovery of a miRNA biomarker that
can display differential expression between races is of great significance for the development and
optimization of miR-4719 and miR-6756-5p-based therapeutic strategies for personalized treatment.
In conclusion, this is the first report to show miR-4719 and miR-6756-5p as potential regulators
of IL-24 mRNA expression and as candidate biomarkers for risk stratification of PCa, as well as
help explain the racial disparity of PCa. Loss of miR-4719 and miR-6756-5p significantly inhibited
proliferation and migration in CRPC cell lines via targeting of IL-24. Consequently, these in vitro studies
also demonstrate the potential of miR-4719 and miR-6756-5p serving as both diagnostic biomarkers
and as therapeutics for CRPC.
4. Materials and Methods
4.1. Cell Culture
Androgen-dependent RWPE-1 cells were cultured in keratinocyte serum-free medium (SFM)
supplemented with 0.05 mg/mL bovine pituitary extract (BPE), 5 ng/mL epidermal growth
factor (EGF) and 1% penicillin-streptomycin. Androgen-independent PC-3 cells were cultured
in F-12K medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.
Androgen-independent DU-145 cells were cultured in MEM supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. Androgen-independent E006AA and E006AA-hT were
cultured in DMEM supplemented with 1% fetal bovine serum and 1% penicillin/streptomycin.
RWPE-1, PC-3, DU-145, Eoo6AA and E006AA-hT cell lines were purchased from the American
Type Culture Collection (Manassas, VA, USA). These cells were cultured at 37 ◦ C in 5% CO2 , under a
humidified atmosphere.
4.2. Transfections of Oligonucleotides
Cells were seeded in six-well plates. After reaching 60–70% confluence, the medium is replaced
with Opti-MEM (Thermo Fisher Scientific Inc.; Wilmington, DE, USA) and cells are transfected
with either a 50 nM non-targeting negative control oligonucleotide (MISSION® Synthetic microRNA
Negative Control, human, product# NCSTUD001), 50 nM miR-4719 (MISSION® microRNA Mimic,
human, product# HMI1756), miR-6756-5p oligonucleotide mimic (MISSION® microRNA Mimic,
human, product# HMI2362), 50 nM miR-4719 (MISSION® microRNA inhibitor, human, product#
HSTUD1756) or miR-6756-5p oligonucleotide inhibitor (MISSION® Synthetic microRNA Inhibitor,
human, product# HSTUD00363) (Sigma-Aldrich, St. Louis, MO, USA), using Lipofectamine RNAiMAX
(Thermo Fisher Scientific Inc.; Wilmington, DE, USA) according to the manufacturer’s instructions.
Transfected cells are then incubated at 37 ◦ C for a total duration of 24 h before cells are lysated.
4.3. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis
MicroRNA isolation was performed using Invitrogen™ mirVana™ miRNA Isolation Kit,
with phenol, (Catalog Number: AM1560) according to manufacturer instructions. cDNA and
qRT-PCR were performed using Qiagen miScript II RT Kit (50) (Catalog Number: 218161) and
Qiagen miScript SYBR® Green PCR Kits (Catalog Number: 218073) (Qiagen, Germantown,
MD, USA), respectively. The following primers were used: RNU6_B12 snRNA primers were
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purchased from Qiagen (Hs_RNU6-2_11 miScript Primer Assay RNU6-6P RNA, U6 small nuclear
6, pseudogene: Product #218300, Catalog Number: MS00033740). Hs_miR-4719_1 miScript
Primer Assay and miR-6756-5p miScript Primer Assay were purchased from Qiagen (hsa-miR-4719:
Product # 218300, Catalog Number: MS00033740) and (has-miR-6756-5p: Product # 218300,
Catalog number: MS00046606). Total RNA was isolated by using Qiagen RNeasy Mini Kit (50)
(Catalog Number 74104). Reverse transcription was performed on 1 µg of total RNA with an
oligo(dT) primer using Qiagen QuantiTect Rev. Transcription Kit (50) (Catalog Number: 205311).
cDNA corresponding to 20 ng of total RNA was amplified for 35 cycles by PCR with specific primers
using Thermo Fisher Applied Biosystems™SYBR™ Green PCR Master Mix (Catalog Number: 4309155).
The following primers were used: IL-24, FORWARD 50 -TTCTCTGGAGCCAGGTATC-30 , REVERSE
5-’TAGAATTTCTGCATCCAGGT-3, GAPDH, FORWARD 50 -AGCTTGTCATCAATGGAAAT-3,
REVERSE 50 -CTTCACCACCTTCTTGATGT-30 .
4.4. MTT Assay
Briefly, cells were plated in 96-well dishes ((1 × 103 )/well), with three replicates for each group and
allowed to attach for 24 h prior to treatment(s). Cell growth and viable cell numbers were monitored
by 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining. The optical density
(OD) value was measured at 595 nm with a microplate reader (Bio-Rad, Hercules, CA, USA).
4.5. Wound Healing Assay
First, 1 × 104 cells were seeded into six-well plates. At 90% confluency, the cell monolayer was
wounded with a 200-µL pipette, washed with PBS, and the medium replaced with OPTI-MEM with
treatments of a 50 nM non-targeting negative control oligonucleotide, 50 nM miR-4719 oligonucleotide
mimic, miR-6756-5p oligonucleotide mimic, 50 nM miR-4719 oligonucleotide inhibitor, or miR-6756-5p
oligonucleotide inhibitor using Lipofectamine RNAiMAX according to the manufacturer. Images were
taken 24 h later. Images were taken using Motic Images Plus 2.0 Software (Motic; Richmond, BC,
Canada) from three experiments and were analyzed for percentage cell-covered area.
4.6. Statistical Analysis
Data were collected from at least three independent experiments. All results are presented
as mean ± standard error of the mean (SEM). Unless otherwise indicated, analysis of statistical
significance of differences between groups was performed using two-tailed Student’s t-test, and only
values with p < 0.05 were deemed significant. For comparison of variables, a Student’s t-test or
analysis of variance (ANOVA) test were used for analysis of each set of continuous and categorical
data. Statistical differences in the relative miRNA expression profiles were determined with one-way
analysis of variance (ANOVA) using the SPSS Statistics software (http://www-01.ibm.com/software/
analytics/spss/) on normalized data. p < 0.05 was considered significant.
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